 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Oxidoreductase
|
PDB id
|
|
|
|
1tg2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Oxidoreductase
|
 |
|
Title:
|
 |
Crystal structure of phenylalanine hydroxylase a313t mutant with 7,8-dihydrobiopterin bound
|
|
Structure:
|
 |
Phenylalanine-4-hydroxylase. Chain: a. Fragment: delta nh 1-102-delta cooh 428 human phenylalanine hydroxylase. Synonym: pah, phe-4- monooxygenase. Engineered: yes. Mutation: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: pah. Expressed in: escherichia coli bl21(de3). Expression_system_taxid: 469008.
|
|
Resolution:
|
 |
|
2.20Å
|
R-factor:
|
0.213
|
R-free:
|
0.254
|
|
|
Authors:
|
 |
H.Erlandsen,A.L.Pey,A.Gamez,B.Perez,L.R.Desviat,C.Aguado, R.Koch,S.Surendran,S.Tyring,R.Matalon,C.R.Scriver,M.Ugarte, A.Martinez,R.C.Stevens
|
Key ref:
|
 |
H.Erlandsen
et al.
(2004).
Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations.
Proc Natl Acad Sci U S A,
101,
16903-16908.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
28-May-04
|
Release date:
|
30-Nov-04
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
|
|
|
P00439
(PH4H_HUMAN) -
Phenylalanine-4-hydroxylase
|
|
|
|
Seq: Struc:
|
 |
 |
 |
452 a.a.
308 a.a.*
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
*
PDB and UniProt seqs differ
at 1 residue position (black
cross)
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.1.14.16.1
- Phenylalanine 4-monooxygenase.
|
|
 |
 |
 |
 |
 |

Pathway:
|
 |
Phenylalanine and Tyrosine Biosynthesis
|
 |
 |
 |
 |
 |
Reaction:
|
 |
L-phenylalanine + tetrahydrobiopterin + O2 = L-tyrosine + 4a-hydroxytetrahydrobiopterin
|
 |
 |
 |
 |
 |
L-phenylalanine
|
+
|
tetrahydrobiopterin
Bound ligand (Het Group name = )
corresponds exactly
|
+
|
O(2)
|
=
|
L-tyrosine
|
+
|
4a-hydroxytetrahydrobiopterin
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Cofactor:
|
 |
Iron
|
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Biological process
|
oxidation reduction
|
2 terms
|
 |
|
Biochemical function
|
monooxygenase activity
|
3 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Proc Natl Acad Sci U S A
101:16903-16908
(2004)
|
|
PubMed id:
|
|
|
|
|
| |
|
Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations.
|
|
H.Erlandsen,
A.L.Pey,
A.Gámez,
B.Pérez,
L.R.Desviat,
C.Aguado,
R.Koch,
S.Surendran,
S.Tyring,
R.Matalon,
C.R.Scriver,
M.Ugarte,
A.Martínez,
R.C.Stevens.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Phenylketonuria patients harboring a subset of phenylalanine hydroxylase (PAH)
mutations have recently shown normalization of blood phenylalanine levels upon
oral administration of the PAH cofactor tetrahydrobiopterin
[(6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4)]. Several hypotheses have been
put forward to explain BH4 responsiveness, but the molecular basis for the
corrective effect(s) of BH4 has not been understood. We have investigated the
biochemical, kinetic, and structural changes associated with BH4-responsive
mutations (F39L, I65T, R68S, H170D, E178G, V190A, R261Q, A300S, L308F, A313T,
A373T, V388M, E390G, P407S, and Y414C). The biochemical and kinetic
characterization of the 15 mutants studied points toward a multifactorial basis
for the BH4 responsiveness; the mutants show residual activity (>30% of WT) and
display various kinetic defects, including increased Km (BH4) and reduced
cooperativity of substrate binding, but no decoupling of cofactor (BH4)
oxidation. For some, BH4 seems to function through stabilization and protection
of the enzyme from inactivation and proteolytic degradation. In the crystal
structures of a phenylketonuria mutant, A313T, minor changes were seen when
compared with the WT PAH structures, consistent with the mild effects the mutant
has upon activity of the enzyme both in vitro and in vivo. Truncations made in
the A313T mutant PAH form revealed that the N and C termini of the enzyme
influence active site binding. Of fundamental importance is the observation that
BH4 appears to increase Phe catabolism if at least one of the two heterozygous
mutations has any residual activity remaining.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Fig. 1. PAH mutations covered in this work mapped onto the
monomer of a composite model of full-length PAH. Orange
represents the regulatory domain (1-142), gray represents the
catalytic domain (143-410), and blue represents the
oligomerization domain (411-452). The iron at the active site is
displayed as a yellow sphere, whereas the tetrahydrobiopterin
(BH[4]), thienylalanine (TIH) substrate analog, and protein side
chains are colored by individual atom colors (green is carbon,
blue is nitrogen, red is oxygen, and yellow is sulfur). The
purple regions are considered the pterin-binding regions.
|
 |
Figure 2.
Fig. 2. (A) Ala-313 environment in wt-PAH composite
full-length model. (B) Thr-313 environment in the
A313T-dt-PAH·7,8-BH[2] structure. The color scheme is as
in Fig. 1.
|
 |
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
M.Staudigl,
S.W.Gersting,
M.K.Danecka,
D.D.Messing,
M.Woidy,
D.Pinkas,
K.F.Kemter,
N.Blau,
and
A.C.Muntau
(2011).
The interplay between genotype, metabolic state and cofactor treatment governs phenylalanine hydroxylase function and drug response.
|
| |
Hum Mol Genet, 20,
2628-2641.
|
 |
|
|
|
|
 |
A.C.Calvo,
T.Scherer,
A.L.Pey,
M.Ying,
I.Winge,
J.McKinney,
J.Haavik,
B.Thöny,
and
A.Martinez
(2010).
Effect of pharmacological chaperones on brain tyrosine hydroxylase and tryptophan hydroxylase 2.
|
| |
J Neurochem, 114,
853-863.
|
 |
|
|
|
|
 |
A.C.Muntau,
and
S.W.Gersting
(2010).
Phenylketonuria as a model for protein misfolding diseases and for the development of next generation orphan drugs for patients with inborn errors of metabolism.
|
| |
J Inherit Metab Dis, 33,
649-658.
|
 |
|
|
|
|
 |
A.Jorge-Finnigan,
C.Aguado,
R.Sánchez-Alcudia,
D.Abia,
E.Richard,
B.Merinero,
A.Gámez,
R.Banerjee,
L.R.Desviat,
M.Ugarte,
and
B.Pérez
(2010).
Functional and structural analysis of five mutations identified in methylmalonic aciduria cblB type.
|
| |
Hum Mutat, 31,
1033-1042.
|
 |
|
|
|
|
 |
C.O.Harding
(2010).
New era in treatment for phenylketonuria: Pharmacologic therapy with sapropterin dihydrochloride.
|
| |
Biologics, 4,
231-236.
|
 |
|
|
|
|
 |
M.I.Flydal,
T.C.Mohn,
A.L.Pey,
J.Siltberg-Liberles,
K.Teigen,
and
A.Martinez
(2010).
Superstoichiometric binding of L-Phe to phenylalanine hydroxylase from Caenorhabditis elegans: evolutionary implications.
|
| |
Amino Acids, 39,
1463-1475.
|
 |
|
|
|
|
 |
S.W.Gersting,
F.B.Lagler,
A.Eichinger,
K.F.Kemter,
M.K.Danecka,
D.D.Messing,
M.Staudigl,
K.A.Domdey,
C.Zsifkovits,
R.Fingerhut,
H.Glossmann,
A.A.Roscher,
and
A.C.Muntau
(2010).
Pahenu1 is a mouse model for tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency and promotes analysis of the pharmacological chaperone mechanism in vivo.
|
| |
Hum Mol Genet, 19,
2039-2049.
|
 |
|
|
|
|
 |
A.Daniele,
I.Scala,
G.Cardillo,
C.Pennino,
C.Ungaro,
M.Sibilio,
G.Parenti,
L.Esposito,
A.Zagari,
G.Andria,
and
F.Salvatore
(2009).
Functional and structural characterization of novel mutations and genotype-phenotype correlation in 51 phenylalanine hydroxylase deficient families from Southern Italy.
|
| |
FEBS J, 276,
2048-2059.
|
 |
|
|
|
|
 |
F.K.Trefz,
D.Scheible,
H.Götz,
and
G.Frauendienst-Egger
(2009).
Significance of genotype in tetrahydrobiopterin-responsive phenylketonuria.
|
| |
J Inherit Metab Dis, 32,
22-26.
|
 |
|
|
|
|
 |
M.Sanford,
and
G.M.Keating
(2009).
Sapropterin: a review of its use in the treatment of primary hyperphenylalaninaemia.
|
| |
Drugs, 69,
461-476.
|
 |
|
|
|
|
 |
M.Sanford,
and
G.M.Keating
(2009).
Spotlight on sapropterin in primary hyperphenylalaninemiadagger.
|
| |
BioDrugs, 23,
201-202.
|
 |
|
|
|
|
 |
M.Stojiljkovic,
B.Pérez,
L.R.Desviat,
C.Aguado,
M.Ugarte,
and
S.Pavlovic
(2009).
The Missense p.S231F phenylalanine hydroxylase gene mutation causes complete loss of enzymatic activity in vitro.
|
| |
Protein J, 28,
294-299.
|
 |
|
|
|
|
 |
S.F.Dobrowolski,
A.L.Pey,
R.Koch,
H.Levy,
C.C.Ellingson,
E.W.Naylor,
and
A.Martinez
(2009).
Biochemical characterization of mutant phenylalanine hydroxylase enzymes and correlation with clinical presentation in hyperphenylalaninaemic patients.
|
| |
J Inherit Metab Dis, 32,
10-21.
|
 |
|
|
|
|
 |
A.L.Pey,
M.Ying,
N.Cremades,
A.Velazquez-Campoy,
T.Scherer,
B.Thöny,
J.Sancho,
and
A.Martinez
(2008).
Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria.
|
| |
J Clin Invest, 118,
2858-2867.
|
 |
|
|
|
|
 |
B.Merinero,
B.Pérez,
C.Pérez-Cerdá,
A.Rincón,
L.R.Desviat,
M.A.Martínez,
P.R.Sala,
M.J.García,
L.Aldamiz-Echevarría,
J.Campos,
V.Cornejo,
M.Del Toro,
A.Mahfoud,
M.Martínez-Pardo,
R.Parini,
C.Pedrón,
L.Peña-Quintana,
M.Pérez,
M.Pourfarzam,
and
M.Ugarte
(2008).
Methylmalonic acidaemia: examination of genotype and biochemical data in 32 patients belonging to mut, cblA or cblB complementation group.
|
| |
J Inherit Metab Dis, 31,
55-66.
|
 |
|
|
|
|
 |
C.Harding
(2008).
Progress toward cell-directed therapy for phenylketonuria.
|
| |
Clin Genet, 74,
97.
|
 |
|
|
|
|
 |
D.Bercovich,
A.Elimelech,
J.Zlotogora,
S.Korem,
T.Yardeni,
N.Gal,
N.Goldstein,
B.Vilensky,
R.Segev,
S.Avraham,
R.Loewenthal,
G.Schwartz,
and
Y.Anikster
(2008).
Genotype-phenotype correlations analysis of mutations in the phenylalanine hydroxylase (PAH) gene.
|
| |
J Hum Genet, 53,
407-418.
|
 |
|
|
|
|
 |
K.Michals-Matalon
(2008).
Sapropterin dihydrochloride, 6-R-L-erythro-5,6,7,8-tetrahydrobiopterin, in the treatment of phenylketonuria.
|
| |
Expert Opin Investig Drugs, 17,
245-251.
|
 |
|
|
|
|
 |
M.R.Zurflüh,
J.Zschocke,
M.Lindner,
F.Feillet,
C.Chery,
A.Burlina,
R.C.Stevens,
B.Thöny,
and
N.Blau
(2008).
Molecular genetics of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency.
|
| |
Hum Mutat, 29,
167-175.
|
 |
|
|
|
|
 |
S.W.Gersting,
K.F.Kemter,
M.Staudigl,
D.D.Messing,
M.K.Danecka,
F.B.Lagler,
C.P.Sommerhoff,
A.A.Roscher,
and
A.C.Muntau
(2008).
Loss of function in phenylketonuria is caused by impaired molecular motions and conformational instability.
|
| |
Am J Hum Genet, 83,
5.
|
 |
|
|
|
|
 |
U.Langenbeck
(2008).
Classifying tetrahydrobiopterin responsiveness in the hyperphenylalaninaemias.
|
| |
J Inherit Metab Dis, 31,
67-72.
|
 |
|
|
|
|
 |
A.L.Pey,
and
A.Martinez
(2007).
Tetrahydrobiopterin for patients with phenylketonuria.
|
| |
Lancet, 370,
462-463.
|
 |
|
|
|
|
 |
A.L.Pey,
F.Stricher,
L.Serrano,
and
A.Martinez
(2007).
Predicted effects of missense mutations on native-state stability account for phenotypic outcome in phenylketonuria, a paradigm of misfolding diseases.
|
| |
Am J Hum Genet, 81,
1006-1024.
|
 |
|
|
|
|
 |
C.R.Scriver
(2007).
The PAH gene, phenylketonuria, and a paradigm shift.
|
| |
Hum Mutat, 28,
831-845.
|
 |
|
|
|
|
 |
L.Wang,
S.Surendran,
K.Michals-Matalon,
G.Bhatia,
S.Tanskley,
R.Koch,
J.Grady,
S.K.Tyring,
R.C.Stevens,
F.Guttler,
and
R.Matalon
(2007).
Mutations in the regulatory domain of phenylalanine hydroxylase and response to tetrahydrobiopterin.
|
| |
Genet Test, 11,
174-178.
|
 |
|
|
|
|
 |
R.Matalon,
K.Michals-Matalon,
G.Bhatia,
A.B.Burlina,
A.P.Burlina,
C.Braga,
L.Fiori,
M.Giovannini,
E.Grechanina,
P.Novikov,
J.Grady,
S.K.Tyring,
and
F.Guttler
(2007).
Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine.
|
| |
J Inherit Metab Dis, 30,
153-158.
|
 |
|
|
|
|
 |
P.T.Clayton
(2006).
B6-responsive disorders: a model of vitamin dependency.
|
| |
J Inherit Metab Dis, 29,
317-326.
|
 |
|
|
|
|
 |
R.Matalon,
K.Michals-Matalon,
G.Bhatia,
E.Grechanina,
P.Novikov,
J.D.McDonald,
J.Grady,
S.K.Tyring,
and
F.Guttler
(2006).
Large neutral amino acids in the treatment of phenylketonuria (PKU).
|
| |
J Inherit Metab Dis, 29,
732-738.
|
 |
|
|
|
|
 |
X.Zhang,
J.M.Beaulieu,
R.R.Gainetdinov,
and
M.G.Caron
(2006).
Functional polymorphisms of the brain serotonin synthesizing enzyme tryptophan hydroxylase-2.
|
| |
Cell Mol Life Sci, 63,
6.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
|